Mahamaya Lifesciences Share Price

Mahamaya Lifesciences Limited was originally incorporated as a private limited Company under the name of Mahamaya Life Sciences Private Limited by the Assistant Registrar of Companies NCT Delhi Haryana on May 07 2002. Further Company name was changed from Mahamaya Life Sciences Private Limited to Mahamaya Lifesciences Private Limited and a fresh Certificate of Incorporation dated February 15 2016 was issued by the Registrar of Companies Delhi. The Company status was changed to Public Limited Company and the name of the Company was changed to Mahamaya Lifesciences Limited on November 19 2024 by the Registrar of Companies Central Processing Centre.The Company specializes in manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies as well as multinational corporations MNCs. The Company began the journey by focusing on import and registration of vital pesticide molecules Technical that were not produced domestically in India. It imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee CIBRC under the Department of Agriculture Government of India. After successful registration it marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs.In 2002 Company expanded from the sale of technical to companies to establish its own manufacturing plant for formulations in December 2021 located in Dahej Gujarat. From this manufacturing facility it produce and sell bulk formulations branded products own brand products and export them to customers. Domestically it market the own branded products across states such as Punjab Haryana Rajasthan Uttar Pradesh Gujarat Maharashtra Andhra Pradesh and Telangana through a wellestablished dealer network. Internationally it export the products to countries including the Dominican Republic Turkey Egypt and the UAE.The Company has introduced Norwegian seaweed extract based Biostimulants formulations. Company is focused on diversifying its portfolio by adding more products in bioproduct category. The expansion of bioproducts in agriculture is a critical strategy to meet the growing demand for sustainable and ecofriendly agricultural solutions. Company also incorporated a subsidiary in UAE named Mahamaya Lifesciences FZE to further promote the import and export operations through this subsidiary in 2017.The Company is planning an IPO of 6178800 Equity Shares of Rs 10/ each comprising a fresh issue of 5638800 Equity Shares and 540000 Equity Shares through offer for sale..

Revenue: ₹117.92Cr as on March 2025 (Q4 FY25)
Net Profit: ₹5.53Cr as on March 2025 (Q4 FY25)